文献速递肝病消化道肿瘤与早癌

S100A11/ANXA2属于在脂肪变早期失调并与炎症和肝细胞癌发展相关的抑癌/致癌网络

S100A11/ANXA2 belongs to a tumour suppressor/oncogene network deregulated early with steatosis and involved in inflammation and hepatocellular carcinoma development.
PubMed 文献 · Gut · 2020-01-09

研究分析自发发生肝细胞癌(HCC)的小鼠脂肪变性肝组织的蛋白质组,并在多种非酒精性脂肪性肝病(NAFLD)/HCC小鼠模型及人样本中验证。发现NAFLD早期即出现一整套抑癌基因/致癌基因(TS/ONC)的非基因组改变,其中S100A11过表达与高级别HCC和不良预后相关,并在体内促进炎症和纤维化。

要点

  • NAFLD早期已出现抑癌/致癌网络非基因组改变,可能促进肝癌发生。
  • S100A11过表达与高级别HCC及不良预后相关。
  • S100A11下调可抑制小鼠炎症和纤维化进展。

核心结论

  • NAFLD相关细胞应激触发整套抑癌/致癌网络非基因组改变,促进肝癌发生。
  • 致癌因子S100A11过表达在体内促进炎症/纤维化,并与高级别HCC及不良预后显著相关。

研究设计与样本

  • 分析自发发生HCC的小鼠脂肪变性肝组织蛋白质组。
  • 在多种NAFLD/HCC小鼠模型及人样本中进一步研究TS/ONC改变。
  • 通过体内、体外和离体分析评估S100A11的炎症、纤维化和致癌功能。

主要发现

  • 在NAFLD小鼠和人中分别发现一整套TS/ONC下调和上调。
  • 这些TS/ONC改变在HCC中保留甚至加剧。
  • S100A11过表达与高级别HCC和不良预后相关。
  • 体内S100A11下调显著抑制胆碱/蛋氨酸缺乏饮食小鼠的炎症和纤维化发展。
  • 体外和离体分析显示S100A11是肝细胞去分化标志物,由癌细胞分泌,促进细胞增殖和迁移。

临床怎么用

  • S100A11过表达可作为高级别HCC及不良预后的关联标志物。
  • 靶向S100A11可能抑制NAFLD相关炎症/纤维化及肝癌发生。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Hepatocellular carcinoma (HCC) development occurs with non-alcoholic fatty liver disease (NAFLD) in the absence of cirrhosis and with an increasing incidence due to the obesity pandemic. Mutations of tumour suppressor (TS) genes and oncogenes (ONC) have been widely characterised in HCC. However, mounting evidence indicates that non-genomic alterations of TS/ONC occur early with NAFLD, thereby potentially promoting hepatocarcinogenesis in an inflammatory/fibrotic context. The aim of this study was to identify and characterise these alterations. DESIGN: The proteome of steatotic liver tissues from mice spontaneously developing HCC was analysed. Alterations of TSs/ONCs were further investigated in various mouse models of NAFLD/HCC and in human samples. The inflammatory, fibrogenic and oncogenic functions of S100A11 were assessed through in vivo, in vitro and ex-vivo analyses. RESULTS: A whole set of TSs/ONCs, respectively, downregulated or upregulated was uncovered in mice and human with NAFLD. Alterations of these TSs/ONCs were preserved or even exacerbated in HCC. Among them, overexpression of S100A11 was associated with high-grade HCC and poor prognosis. S100A11 downregulation in vivo significantly restrains the development of inflammation and fibrosis in mice fed a choline/methionine-deficient diet. Finally, in vitro and ex-vivo analyses revealed that S100A11 is a marker of hepatocyte de-differentiation, secreted by cancer cells, and promoting cell proliferation and migration. CONCLUSION: Cellular stress associated with NAFLD triggers non-genomic alterations of a whole network of TSs/ONCs fostering hepatocarcinogenesis. Among those, overexpression of the oncogenic factor S100A11 promotes inflammation/fibrosis in vivo and is significantly associated with high-grade HCC with poor prognosis.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Sobolewski C, Abegg D, Berthou F, et al. S100A11/ANXA2 belongs to a tumour suppressor/oncogene network deregulated early with steatosis and involved in inflammation and hepatocellular carcinoma development. Gut. 2020. PMID: 31919231. doi:10.1136/gutjnl-2019-319019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。